Predominant gonorrhea lineage in Europe is resistant to first-line treatments – Medical Xpress

Share Article


Forget Password?
Learn more
share this!
22
4
Share
Email
September 19, 2022
by FISABIO
A study featuring the participation of Fisabio (Foundation for the Promotion of Health and Biomedical Research of Valencia Region), dependent on the Conselleria de Sanitat Universal i Salut Pública, has found that the predominant lineage in Europe of gonococcus—the bacterium which causes gonorrhea—is resistant to one of the two drugs, among others, most commonly used today to treat this disease.

The bacterium Neisseria gonorrhoeae, commonly known as gonococcus, is the cause of gonorrhea, a that is estimated to affect 82 million people worldwide each year. In this context, surveillance of its lineages is necessary to establish the most effective treatments with .
Leonor Sánchez-Busó, a researcher at Fisabio and Plan GenT of the Conselleria de Sanitat Universal i Salut Pública, says, “Compared to two previous surveillance programs, the results of this genomic surveillance study show the expansion of a lineage throughout Europe that is resistant to azithromycin, which compromises the most common treatment for these infections.”
This study is an resulting from a resistance surveillance program within the framework of the European Gonococcal Antimicrobial Surveillance Program (Euro-GASP) organized by the European Center of Disease Prevention and Control and in which the Center for Genomic Pathogen Surveillance (Oxford University, United Kingdom), the U.K. Health Protection Agency (London, United Kingdom) and the World Health Organization Collaborating Center in Örebro University Hospital (Sweden) also participated.
The methodology consisted of genomic sequencing and the analysis of 2,375 gonococcus isolates collected in 2018 in 26 countries of the European Economic Area. With this material, links between different genomic lineages, antimicrobial resistance and epidemiological information have been analyzed.
“This lineage contains in its genome a mosaic in the mtrCDE efflux pump that causes resistance to azithromycin, and is significantly associated with pharyngeal infections in risk groups. Fortunately, this collection from 2018 does not show mutations that could compromise treatment of this infection with potential new antibiotics, such as zoliflodacin or gepotidacin,” explains Sánchez-Busó, lead author of the article.
The study has been published in The Lancet Microbe and will be of great importance to study the introduction and dynamics of lineages with resistance to antibiotics in Europe as well as in the Valencian Community. One of the researcher’s lines of work is this resistance in the Valencian Community, for which she collaborates with the hospitals of the Valencian public network.
Specifically, 13 hospitals in the community have collaborated or will soon collaborate in supplying samples for gonococcus surveillance tasks. In the province of Valencia, the Hospital Universitario de la Ribera, the Hospital Universitario y Politécnico La Fe, the Hospital General Universitario in València, the Hospital Comarcal Francesc de Borja, the Hospital Clínico Universitario in Valencia, the Hospital Arnau de Vilanova, the Hospital Universitario Doctor Peset and the Hospital Lluís Alcanyís in Xàtiva and the Hospital de Manises.
In the rest of the territory, the Hospital Universitario Sant Joan in Alicante, the Hospital Universitario de La Plana, the Hospital General Universitario in Castellón and the Hospital Comarcal in Vinaròs contribute or will contribute to the research. In addition, work continues on the incorporation of new centers that allow better coverage of the entire territory of the Valencian Community.


Explore further

New strain of extensively drug-resistant Neisseria gonorrhoeae detected in Austria


More information: DOI: 10.13039/501100011033. Leonor Sánchez-Busó et al, Europe-wide expansion and eradication of multidrug-resistant Neisseria gonorrhoeae lineages: a genomic surveillance study, The Lancet Microbe (2022). DOI: 10.1016/S2666-5247(22)00044-1
Provided by FISABIO

Citation: Predominant gonorrhea lineage in Europe is resistant to first-line treatments (2022, September 19) retrieved 19 September 2022 from https://medicalxpress.com/news/2022-09-predominant-gonorrhea-lineage-europe-resistant.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further
Facebook
Twitter
Email
Feedback to editors
8 hours ago
1
8 hours ago
0
Sep 15, 2022
0
Sep 15, 2022
0
Sep 14, 2022
0
30 minutes ago
39 minutes ago
58 minutes ago
1 hour ago
1 hour ago
2 hours ago
3 hours ago
Jun 16, 2022
Feb 28, 2019
Aug 03, 2022
Aug 30, 2018
Sep 13, 2017
Sep 02, 2016
5 hours ago
Sep 16, 2022
Sep 16, 2022
Sep 16, 2022
Sep 16, 2022
Sep 16, 2022
Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use our contact form. For general feedback, use the public comments section below (please adhere to guidelines).
Please select the most appropriate category to facilitate processing of your request
Thank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.
Your email address is used only to let the recipient know who sent the email. Neither your address nor the recipient’s address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.

Get weekly and/or daily updates delivered to your inbox. You can unsubscribe at any time and we’ll never share your details to third parties.
More information Privacy policy
Daily science news on research developments and the latest scientific innovations
The latest engineering, electronics and technology advances
The most comprehensive sci-tech news coverage on the web
This site uses cookies to assist with navigation, analyse your use of our services, collect data for ads personalisation and provide content from third parties. By using our site, you acknowledge that you have read and understand our Privacy Policy and Terms of Use.

source

You might also like

Surviving 2nd wave of corona
COVID-19

Surviving The 2nd Wave of Corona

‘This too shall pass away’ this famous Persian adage seems to be defeating us again and again in the case of COVID-19. Despite every effort

@voguewellness